Keros Therapeutics (KROS) vs Q32 Bio (QTTB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Q32 Bio (QTTB) has outperformed Keros Therapeutics (KROS) over the past year, gaining 157.4% versus a loss of 25.9%. Over five years, KROS leads with a -69.4% price change compared with -92.5% for QTTB. Q32 Bio is the larger company by market cap ($248.3 million vs $236.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KROS | QTTB |
|---|---|---|
| Share price | $11.95 | $8.34 |
| Market cap | $236.93M | $248.28M |
| 1-day change | +2.66% | +3.09% |
| YTD return | -41.31% | +151.20% |
| 1-year return | -25.87% | +157.41% |
| 5-year return | -69.35% | -92.53% |
| P/E ratio (TTM) | — | 2.65 |
| EPS (TTM) | $-3.22 | $3.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $22.55 | $23.57 |
| 52-week low | $9.69 | $1.91 |
| Distance from 52-week high | -47.01% | -64.62% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +65.94% | +374.82% |
| Average volume | 194.05K | 1.38M |
| Shares outstanding | 19.83M | 29.77M |
| Employees | 92 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- QTTB has outperformed KROS by 183.3 percentage points over the past year.
About Keros Therapeutics
KROS stock →Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Q32 Bio
QTTB stock →Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
KROS vs QTTB FAQ
Which is bigger, Keros Therapeutics or Q32 Bio?
Q32 Bio (QTTB) is larger, with a market capitalization of $248.28M compared with $236.93M for Keros Therapeutics (KROS).
Which stock has performed better over the past year, KROS or QTTB?
QTTB returned +157.41% over the past 12 months, compared with -25.87% for KROS (price return, excluding dividends). Past performance does not predict future results.
Are Keros Therapeutics and Q32 Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.